Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3648_Библиотеки_им_академика_М_И_Перельмана
.pdf
8 Medical Management oftheLimb Salvage Inpatient
93
study found that hypoglycemia was relatively
uncommon at weight-based doses below 0.6
units/kg. Above that threshold, hypoglycemia
became much more common [45].
A patient should not be started on sliding
scale insulin alone [39]. Sliding scale insulin
is not a physiologic therapy. When used in this
way, insulin treats hyperglycemia that has
already occurred, so the body has already been
exposed to the elevated glucose. By contrast,
basal-bolus insulin, in which a basal rate of
insulin is delivered along with prandial boluses
to address postprandial glucose spikes, prevents hyperglycemia in the first place [46].
Sliding scale insulin has been associated with
worse glycemic control overall. One study of
hospitalized patients found that patients
treated with sliding scale insulin had a mean
glucose level 20mg/dL higher than a similar
group on basal-bolus insulin [46]. The randomized, controlled RABBIT 2 trial also
noted a significant improvement in glycemic
control in inpatients treated with basal-bolus
insulin. These patients had a daily mean glucose level 27mg/dL lower than those treated
with sliding scale insulin [47].
Perioperative Insulin Management
A patient’s insulin regimen needs adjustment
prior to surgery. All oral antidiabetic medications should be held in the perioperative period.
The ADA recommends giving basal insulin at
60–80% of the full dose the night before the
operation. In a 2017 study, patients who received
100% of their previous insulin dose the night
before surgery had higher rates of hypoglycemia than patients who received 60–87% of their
previous dose. The patients receiving the
reduced dose of insulin were more likely to be
within the goal range of 100–180mg/dL during
the operation [39]. From a review in
Anesthesiology on perioperative hyperglycemia,
Tables 8.1 and 8.2 recommend the following
insulin regimens on the day before and day of
surgery [38].
The review recommends that patients with
type 1 diabetes receive 80% of their usual basal
dose the evening before surgery and 80% again
the morning of. In diabetic patients receiving
morning doses of insulin, the NPH should be
reduced to 50% of the usual dose and longer acting insulins reduced to 60–80%. Prandial insulin
should be held at the time the patient becomes
NPO [38].
Preparation forDischarge
Education
A patient nearing discharge should be prepared
for continued diabetes management at home. The
ADA recommends reviewing the patient’s outpatient diabetes provider, the patient’s understanding of their diagnosis, how to monitor glucose
levels, recognition and plan of action for hyperglycemia and hypoglycemia, a healthy nutrition
plan or referral to diabetes dietician, and the
patient’s antidiabetic medications [39]. A recent
Table 8.1 Standard recommendations for day before surgery insulin regimens
Day before surgery insulin regimens based on oral intake status
Day before surgery
insulin regimens
Normal diet until
midnight (includes those
permitted clear liquids
until 2h prior to surgery)
Bowel prep (and/or clear
liquids only 12–24h prior
to surgery)
Glargine or
detemir
AM
PM
dose
dose
Usual
80% of
dose
usual
dose
Usual
80% of
dose
usual
dose
NPH or 70/30
insulin
AM
dose
80% of
usual
dose
80% of
usual
dose
PM
dose
80% of
usual
dose
80% of
usual
dose
Lispro, aspart,
glulisine, regular Non-insulin injectables
AM
dose
Usual
dose
Usual
dose
PM
dose AM dose PM dose
Usual
dose
Usual
dose
Usual dose Usual dose
Hold when
starting clear
liquid diet/
bowel prep
Hold when
starting clear
liquid diet/
bowel prep

94
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
M. M. Alternburg et al.
Table 8.2 Standard recommendations for day of surgery
insulin regimens
Day of surgery insulin regimens
Lispro,
Glargine or
detemir
80% of usual
dose if
patient uses
twice daily
basal therapy
BG blood glucose
a
6.6mmol/L
NPH or 70/30
insulin
50% of usual
dosea if BG
120mg/dL
Hold for BG
<120mg/dL
aspart,
glulisine,
regular
Hold Hold
Noninsulin
injectables
review of inpatient diabetes education notes that
although most diabetes education occurs in the
outpatient setting, hospitalization is an ideal time
to provide this education. There is growing evidence for the benet of inpatient diabetes education, particularly on reducing readmission rates
and improving health outcomes [48].
Home Medication Management
While a patient is admitted, a hemoglobin A1c
should be obtained if none is identied within the
last 3months. Based on this value, the Endocrine
Society suggests an algorithm for discharge medication management that the ADA subsequently
found to be useful. If the patient’s hemoglobin A1c
is <7%, there should be no change made to the
home diabetes regimen. If the patient has a hemoglobin A1c of 7–9%, the patient has suboptimal
control. At discharge, the patient should be considered for intensied oral medication or basal insulin.
If the hemoglobin A1c is >9%, the patient’s diabetes is poorly controlled. These patients should be
considered for a basal-bolus insulin regimen. This
discharge algorithm was found to be safe and efcacious in a prospective trial. The study started
patients with a hemoglobin A1c of 7–9% on home
glargine at 50% of the hospital dose and patients
with hemoglobin >9% on glargine or basal-bolus at
80% of their hospital dose. The patient should otherwise be restarted on their pre-admission oral antidiabetic medications at discharge [49].
Prevention ofAtherosclerotic Disease
A diabetic patient’s admission presents an ideal
time to ensure that they are on all recommended
medications for comorbid conditions. Many limb
salvage patients with diabetes also have PAD, a
form of atherosclerotic disease. For secondary
prevention, diabetic patients of all ages with atherosclerotic disease should be started on a highintensity statin and aspirin 81 mg daily and
should be considered for an ACE inhibitor or
angiotensin receptor blocker (ARB) medication
[50]. A diabetic patient aged 40–70 even without
atherosclerotic disease should be started on a
medium-intensity statin for primary prevention.
Diabetic patients over 50 without atherosclerotic
disease but with other risk factors likely benet
from a high-intensity statin [50].
Goal Hemoglobin A1c Ranges
Providers should also review goal hemoglobin
A1c ranges with patients. There is no consensus
guideline for goal hemoglobin A1c, so the discussion should be individualized and take into
account patient preference, patient characteristics
and comorbidities, and pre-existing complications of diabetes. The ADA 2020 Glycemic
Control guideline states that a goal hemoglobin
A1c of <7% is appropriate for many patients to
prevent microvascular and macrovascular complications. However, for patients with a history of
severe hypoglycemia, limited life expectancy,
advanced macrovascular or microvascular complications, extensive comorbidities, or longstanding diabetes, a goal of <8% may be more
reasonable [33]. Many limb salvage patients
already have advanced macrovascular and microvascular complications in the forms of PAD and
diabetic neuropathy, likely making the <8% goal
more appropriate. Similarly, American College
of Physician guideline suggests a goal hemoglobin A1c of 7–8% for most patients [51]. Providers
should discuss these factors with each patient to
set a reasonable, individualized goal.
Follow-Up
Appropriate outpatient follow-up is for diabetic
patients. The ADA recommends follow-up with
a primary care physician, diabetes educator, or
endocrinologist within 1month of discharge for
all patients. If the patient’s medications were
adjusted while inpatient or on discharge, the

8 Medical Management oftheLimb Salvage Inpatient
95
ADA recommends follow-up within 1–2weeks
[39]. Coordination of care does not end with
hospital discharge; the internist should ensure
that the discharge summary includes any medication changes communicated to the outpatient
physician.
Section 3: Anticoagulation
andAntiplatelet Management
Background
Many patients requiring limb salvage surgery
will be chronically on anticoagulation or antiplatelet agents. Managing these medications
perioperatively is a challenging task as interruption increases the risk of thromboembolic events
and continuation through a procedure increases
the risk of bleeding. Interruption in anticoagulation for invasive procedures confers a risk of an
adverse event from a VTE or cardioembolic
cerebrovascular accident (CVA). The RE-LY
trial (Randomized Evaluation of Long-Term
Anticoagulant Therapy) showed that of 4591
people who underwent a procedure there was a
1.2% risk of cardioembolic events dened as
CVA, cardiovascular death, and pulmonary
embolism (PE) [52]. Care of the surgical patient
on chronic anticoagulation presents risks both of
thrombosis and bleeding. A methodical assessment of the patient-specic thrombosis risk and
the surgery-specic bleeding risk is essential in
the care of these patients. We will focus on
patients who are anticoagulated for a history of
venous thromboembolism (VTE), atrial brillation, and prosthetic heart valves and outline
decision- making in the surgical setting.
Thrombotic Risk
The rst step in decision-making involves an estimation of the patient’s thrombotic risk.
Thrombotic risk in a patient with a history of
deep venous thrombosis and/or pulmonary embolism is affected by the timeline of thrombotic
events, the presence of an underlying hypercoagu-
lable state, and the presence of active malignancy.
Patients with a recent DVT/PE within 3months or
who have a known severe thrombophilia including antiphospholipid syndrome or deciency of
protein S, C or antithrombin1 [53] are at highest
risk of recurrent thrombosis. Moderate risk
patients include those who have had a VTE
3–12months ago, recurrent VTE, active cancer or
presence of non-severe risk factors for thrombophilia including heterozygous factor V Leiden or
prothrombin gene mutation1. Patients with a
DVT/PE greater than 12months prior to surgery
have a low risk of thromboembolic events.
Thrombotic risk with atrial brillation accounts
for the largest proportion of patients on anticoagulation. Disruption of systemic anticoagulation
increases the risk of a cardioembolic stroke. These
patients represent a diverse group which can be
further risk stratied based on the prevalence of
risk factors including age, sex, hypertension, diabetes, prior CVA, congestive heart failure, and
other vascular disease. These variables can be
used to calculate a CHA2DS2- VASc score. The
score is proportional to stroke risk with a score of
0–3 indicating a low risk for stroke. A score of
4–6 indicating a moderate risk, and a score of 7–9
indicating a high risk for cardioembolic stroke. A
CVA or transient ischemic attack (TIA) within the
past 3months or having rheumatic valvular heart
disease also makes the patient at high risk for a
thromboembolic event [54].
Thrombotic risk also needs to be assessed for
patients with mechanical prosthetic heart valves.
These patients can be further risk stratied based
on which valve has the prosthesis and the presence of additional medical comorbidities. Lowrisk patients include those with bileaet aortic
valve prosthesis without atrial brillation or additional risk factors for CVA.Moderate risk patients
are those with bileaet aortic valve prosthesis
plus one or more comorbidities including atrial
brillation, prior CVA or TIA, diabetes, hypertension, congestive heart failure, or age greater
than 75years. Patients who are at highest risk for
a thromboembolic event include anyone with a
CVA/TIA in the past 6months, any mitral valve
prosthesis, and presence of a caged-ball or tilting
disc aortic valve prosthesis [54].

96
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
M. M. Alternburg et al.
Bleeding Risk
The second step in decision-making about anticoagulant therapy involves a review of the
surgery- specic bleeding risk.
Having assessed our patients’ risk of thrombosis, next we turn our attention to the risk of surgical bleeding. Bleeding risk is determined by the
type of procedure being performed. By denition, procedures that have a 2-day major bleeding
risk of 2–4% are high-risk bleeding procedures;
procedures with a bleeding risk of 0–2% are lowrisk bleeding procedures [54]. Limb salvage surgery is typically a low risk of bleeding procedure
and therefore discussion here will be limited to
low-risk procedures.
Now that we have assessed the patient-specic
thrombotic risk and the surgery-specic bleeding
risk, the decision on whether to disrupt anticoagulation can be made. For procedures with a very
low risk of bleeding, anticoagulation can often be
continued throughout the perioperative period.
This would apply only to simple and supercial
debridement. Limb salvage surgery is often
urgent and may be complex; therefore, interruption of anticoagulation is usually necessary. If
anticoagulation is held for a procedure, it should
be stopped for a time that is sufcient for the anticoagulation effects to resolve. I will review the
common anticoagulants including vitamin K
antagonists, unfractionated heparin, low molecular weight heparin (LMWH), direct thrombin and
direct Xa inhibitors and antiplatelet agents.
Anticoagulants
Warfarin
Warfarin is a vitamin K antagonist that inhibits
factors II, VII, IX, and X.It is monitored using
prothrombin time (PT) and international normalized ratio (INR). Warfarin should be discontinued
5days prior to surgery for a goal INR of less than
1.51 [55]. Check INR on the day prior to surgery
and if the INR is greater than 1.5, oral vitamin K
can be given (1–2 mg). Coumadin should be
restarted 12–24h after the last planned procedure
[55]. If the procedure is urgent/emergent, couma-
din can be reversed. Oral or IV vitamin K
(2.5–5 mg) can be effective in 1–2days. If the
surgery is emergent, fresh frozen plasma (FFP) or
four factor prothrombin complex concentrate
(4F-PCC) can be given.
Since VKA antagonists must be held for days
prior to surgery, patients at high risk of thrombosis will require the interval use of short acting
anticoagulants such as low molecular weight
heparin or unfractionated IV heparin. This practice is call “bridging anticoagulation.” Bridging
reduces the amount of time a patient is not anticoagulated and thereby reduces thrombotic and
cardioembolic events. Bridging is primarily used
for long-acting anticoagulants such as coumadin.
Bridging anticoagulation also increases the risk
of surgical bleeding. In patients who are at a high
risk for a cardioembolic event (recent dvt/pe,
atrial brillation with a high CHADs2Vasc score,
and high-risk mechanical heart valves), bridging
with an unfractionated heparin drip or LMWH is
indicated. Patients with low risk of thrombosis do
not require bridging. Bridging is achieved by
dosing LMWH (enoxaparin 1mg/kg every 12h
or dalteparin 100 units/kg every 12h) or starting
an unfractionated heparin drip either 3days prior
to surgery (2 days after stopping coumadin) or
when INR is no longer in the therapeutic range
[55]. Discontinue LMWH 24h prior to the procedure. Discontinue an unfractionated heparin drip
4–5 h prior to the procedure. After the last
planned procedure, Warfarin may be resumed
that day, and LMWH or an unfractionated heparin drip is typically started 24–48h after the procedure assuming adequate hemostasis. The short
acting heparinoids and coumadin are overlapped
and both continued until the INR is in a therapeutic range for at least 24h [55]. At that point the
heparin or LMWH can be stopped as the patient
is therapeutic on their warfarin.
Direct Thrombin andDirect Xa
Inhibitors
The direct Xa inhibitors include apixaban and
rivaroxaban and the direct thrombin inhibitors
include dabigatran. These medications are also
known as the DOACs. The timing of discontinuing
these medications was studied in the perioperative

8 Medical Management oftheLimb Salvage Inpatient
97
anticoagulation use for surgery evaluation
(PAUSE) trial. This study standardized the time in
which DOACs that were being taken for atrial
brillation were held. It showed the rates of major
bleeding as less than 2% and ischemic stroke as
less than 0.5%. Based on this data, for low to moderate risk procedures, DOACs should be stopped
1day prior to a procedure and resumed 1day after
surgery [56]. One exception is that dabigatran
should be held 2days prior to the procedure if the
creatinine clearance is 30–505,6. Reversal of these
agents is not typically necessary but is available.
Dabigatran can be reversed by idarucizumab.
Apixaban and rivaroxaban can be reversed by
andexanet alfa. Because of the much shorter halflife, DOACs do NOT require bridging anticoagulation with heparin/or LMWH. You simply stop
the agent 1–2 days prior to surgery and resume
postoperatively once adequate hemostasis is
obtained. We are more conservative in resuming
NOACs and DOACs postoperatively, and in general prefer waiting 48–72h after surgery.
Antiplatelet Agents
Antiplatelet agents include aspirin, clopidogrel,
prasugrel, and ticagrelor. Aspirin irreversibly
inhibits platelet cyclooxygenase. Clopidogrel,
prasugrel, and ticagrelor are platelet P2Y12
receptor blockers. Aspirin can be used as a monotherapy or in combination with one of the P2Y12
receptor blockers which is referred to as dual
antiplatelet therapy (DAPT).
Aspirin monotherapy is used for both primary
and secondary prevention of cardiovascular
events including myocardial infarction (MI) and
CVA.The POISE-2 trial suggests that discontinuing aspirin for noncardiac surgery reduces
bleeding without increasing cardiovascular
events. Aspirin should be held 5–7days prior to
surgery and restarted when there is no longer a
risk for major bleeding [57].
One of the primary indications for DAPT is following a percutaneous intervention (PCI). These
patients are at an increased risk for MI or stent
thrombosis, and premature cessation of DAPT is
the strongest risk factor for these complications
[58]. Per the 2016 ACC/AHA guidelines, surgery
would ideally be delayed until 6months following
PCI regardless of the stent type. If a bare metal
stent was placed, then DAPT may be discontinued
as soon as 30days after PCI.If a drug-eluting stent
was placed, DAPT should be continued for
6months after PCI, but if the surgery is urgent discontinuation may be considered after 3 months
[59]. When DAPT is interrupted, aspirin should be
held 5–7days prior to the procedure. Clopidogrel
should be held 5 days prior to the procedure.
Prasugrel should be discontinued 7days prior to
surgery. Ticagrelor should be discontinued
3–5days prior. DAPT can be restarted when there
is no longer a risk for major bleeding.
In practice, many of the limb salvage patients
have strong indications for antiplatelet therapies.
Care coordination with the surgical team is critical in decision-making. Often, DAPT can be continued if surgical bleeding is controlled. Where
possible, we recommend at least continuing aspirin in the high-risk patients with a history of cardiac or peripheral arterial stenting.
Venous Thromboembolism (VTE)
Prophylaxis
DVT/PE is a common postoperative problem and
one of the most preventable types of hospital morbidity/mortality [60]. Limb salvage surgery is
typically a lower risk procedure for major bleeding. LMWH can therefore be started 12h prior to
surgery and resumed 2–12h after a procedure. The
most commonly used agents include enoxaparin
40mg every 24h and dalteparin 5000 units every
24h [61]. An alternative is fondaparinux, which is
started 6–8h postoperatively and dosed at 2.5mg
every 24h [62]. In patients with advanced kidney
disease, subcutaneous unfractionated heparin at
5000 q8 h is recommended. VTE prophylaxis
should be continued until the patient becomes
ambulatory or until hospital discharge.
Summary ofAnticoagulation
Management of anticoagulation in the surgical
setting is one of the most high-risk areas of medical decision-making. Resuming anticoagulation

98
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
M. M. Alternburg et al.
after surgery requires careful coordination with
the surgical team. In general, full anticoagulation
is usually permitted 48h after surgery. This timeline can be accelerated to 24h post-procedure in
low-risk bleeding situations or extended to 72h
or longer if signicant surgical bleeding is
encountered. Other factors that will delay the
resumption of full anticoagulation include neuroaxial anesthesia with a lumbar epidural catheter
and a history of postoperative bleeding. In settings where there is not full condence that anticoagulation will be tolerated, we recommend
beginning a heparin drip as it can be most rapidly
stopped and/or reversed. If the heparin drip is tolerated, then the patient can be transitioned back
to their outpatient regimen. The reason for the
longer wait period for the DOACs is that they are
not readily reversible. With the complicated management decisions and potential life-threatening
possibilities of DVT/PE, stroke, and postoperative bleeding, regular communication between
the surgical and medical teams is essential.
Section 4: Postoperative
Complications
Postoperative complications are common in the
hospitalized patient and require prompt medical
evaluation and treatment. The limb salvage
patients are at higher risk of complications due to
their underlying age and comorbidities including
diabetes, vascular disease, chronic kidney disease.
Medical complications increase length of stay,
morbidity, and mortality. We will focus on the recognition and treatment of acute kidney injury,
delirium, and postoperative gastrointestinal complications. Development of complications can
affect a patient’s readiness for the operating room
and also for safe hospital discharge. The internist
must work in careful coordination with the surgical team as delay in surgery may be required.
Acute Kidney Injury
Acute kidney injury (AKI) is a common complication in surgical patients undergoing limb sal-
vage treatment. The limb salvage patients have an
increased rate of underlying chronic kidney disease which further increases their risk for AKI.A
thorough evaluation to determine the etiology of
the decline in kidney function involves an assessment of the patient’s volume status, a review of
potentially reno-toxic medications and evaluation to rule out obstruction.
Pre-renal AKI can be triggered by volume
depletion or hypotension. Limb salvage patients
are at increased risk of volume depletion due to
NPO status for multiple days due to staged procedures. Poor oral intake is common in the postoperative setting due to postoperative nausea and
vomiting (PONV), sedation due to narcotic analgesia and delirium. Hypotension is another
known precipitator of pre-renal AKI.Hypotension
occurs preoperatively in patients with severe sepsis, intraoperatively due to anesthetic response or
surgical blood loss, and postoperatively due to
the effects of opioid analgesia.
Intrinsic injury to the kidney occurs from
direct nephrotoxicity from medications and contrast agents. Common culprits include intravenous antibiotic, intravenous contrast, and
NSAIDs. Contrast induced nephropathy is much
less common now that lower osmolality contrast
agents are utilized [63]. Renal injury from contrast is possible in patients with an estimated GFR
less than 30 and in patients with a recent AKI
[64]. Likewise, directed angiography to assess for
peripheral vascular disease now can involve
smaller amounts of contrast. Antibiotic associated
nephropathy is also common. Careful monitoring
of dosing and drug levels for vancomycin is recommended to help reduce the incidence of
toxicity.
Urinary tract obstruction also occurs in the surgical patient. It can be precipitated by urinary
retention due to spinal/epidural anesthesia, postoperative ileus, and medications. Mechanical obstruction more commonly occurs in male patients with
underlying BPH.A simple bladder scan to check
post void residual will detect both of these obstructive causes of AKI.A renal US is needed to rule out
the less common etiologies of obstruction such as
ureteral obstruction due to anatomic problems,
nephrolithiasis, malignant processes.

8 Medical Management oftheLimb Salvage Inpatient
99
Delirium
Delirium is common in the hospitalized patient,
affecting up to 50% of hospitalized patients and
may be preventable in as much as 30–40% of
cases [65]. The development of delirium is associated with increased length of stay, increased
risk of discharge to a nursing facility, and
increased risk of death. Risk factors for delirium
include dementia or cognitive impairment, functional impairment, vision impairment, history of
alcohol abuse, age >70, comorbidity burden,
polypharmacy, psychoactive medication use,
physical restraints, and anormal laboratory values [65].
Initial evaluation of delirium should include
ascertaining baseline mental status cognitive
function utilizing information obtained from the
patient, family, and other caregivers. It is important to determine the patient’s pre-morbid cognitive status so that subtle changes will be noticed
and identied early. The initial exam should be
focused to screen out acute physiologic problems
such as hypoxemia, hypoventilation, hypoglycemia, acute cardiac decompensation. Next steps
include medication review, assessment of metabolic derangements, ruling out intercurrent or
intreated infection, checking an EKG to evaluate
for silent ischemia, with consideration of neuroimaging reserved for cases where the exam is
focal, head trauma suspected, or a complete evaluation has failed to yield a suspected etiology.
While often multifactorial in etiology, identication, and removal of inciting factors along with
careful application of delirium protocols can help
to minimize the consequences of delirium.
Simple non-medical interventions such as
keeping shades up/lights on during daytime, frequent reorientation, therapeutic activities, maintaining hydration and nutrition, and providing
vision and hearing aids such as is described in
the Hospital Elder Life Program (HELP) and
help with prevention [66]. Minimization of psychoactive medications such as narcotic analgesics, muscle relaxants, benzodiazepines will
help the patient to clear their delirium. The addition of antihistamines, sedative hypnotics, and
anti- psychotic medications should be avoided
where possible [65]. Current recommendations
do not support the use of anti-psychotic medications [67].
Postoperative GI Complications
Common gastrointestinal complications that will
be addressed include postoperative nausea and
vomiting (PONV), opioid induced constipation
(OIC), postoperative ileus (POI), and antibiotic
associated diarrhea. The internist should be prepared to institute preventive therapies, recognize
complications, and implement appropriate treatment options.
Postoperative Nausea andVomiting
Postoperative nausea and vomiting (PONV) is a
term used to describe a patient’s nausea and vomiting in the immediate 24h post-procedure. If not
managed properly, PONV can lead to prolonged
hospitalizations, patient dissatisfaction, and even
severe medical complications like aspiration and
wound dehiscence. A strategic approach for treatment of PONV includes identifying high-risk
patients, using prophylactic antiemetics, and
understanding the different treatment options.
Table8.3 is a simplied risk calculator that can
be sued to decide if prophylactic PONV treatment is appropriate.
While medical treatment options for PONV
can differ based on hospital formularies and a
patient’s underlying disease, there are several
other strategies that can be universally applied.
PONV can be reduced when using combination
antiemetics from different classes, using localized instead of generalized anesthesia if possible,
ensuring patient hydration, and providing ade-
Table 8.3 Simplied risk calculator by Apfel [68] that
can be used to decide if prophylactic PONV treatment is
appropriate
Risk factors (1 point
each) Points
Female 0–1 10–20
Non smoker 2–3 40–60
History of PONV 4 80
Post operative opioids
Prevalence of PONV
(%)

100
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Table 8.4 List of commonly used antiemetics and their side effects. For maximum efcacy, a rescue treatment should
include an antiemetic from a different class than the ones that were used for prophylaxis unless signicant time has
passed
Drug class Example Side effects
Serotonin 5-hydroxytryptamine
type 3 (5-HT3) receptor
antagonists
Glucocorticoids Dexamethasone Slow onset, can interfere with cell counts and glucose
Anticholinergic Scopolamine Slow onset, dry mouth, blurry vision, confusion or
Antidopaminergic Droperidol Sedation, cardiac arrythmias and sudden cardiac deaths
Antihistamine Diphenhydramine,
Ondansetron QTc prolongation
metabolism
agitation in older adults, acute angle closure glaucoma
Sedation, dry mouth, dizziness, urinary retention
promethazine
M. M. Alternburg et al.
quate pain control. Common antiemetics and
their side effects are listed in Table8.4.
Opioid Induced Constipation
Opioid induced constipation (OIC) is a common
manifestation of chronic or acute opioid use. To
diagnose OIC, we use the Rome IV criteria which
include new or worsening constipation symptoms
when opioids are initiated or increased. Prevention
is the recommended treatment strategy for OIC
and can include an osmotic laxative like polyethylene glycol or a stimulant laxative like senna.
Additional modications to consider are proper
hydration, increased mobility, and adequate
dietary ber intake. It is reasonable to up titrate
the frequencies of current management or con-
Fig. 8.2 Megacolon measuring 16.3cm on plain abdominal radiograph (author’s own image)
sider adding another agent for those patients who
develop OIC despite a preventative regimen. If a
patient is refractory to increase of the current
lactose intolerant patients as it may cause abdominal discomfort [70].
management, if ileus and obstruction have been
ruled out, it is important to consider impaction as
the source of the constipation. Mineral oil enemas
and soap water enemas are useful and safe.
Peripherally acting mu-opioid receptor antagonists (PAMORAs) should be reserved for refractory OIC in the absence of bowel obstruction.
Ultimately, we suggest following the regimen
that is most effective and best tolerated by the
patient. However, there are two important considerations worth mentioning when choosing a
bowel regiment including eet enemas and lactulose. Fleet enemas should be avoided in patients
with renal failure as they contain high amounts of
phosphate [69]. Lactulose should not be used in
Postoperative Ileus
Postoperative ileus (POI) is a physiologic process
that is usually benign and typically resolves by
postoperative day 3. The proposed physiology of
POI is multimodal and includes gastrointestinal
dysmotility secondary to bowel inammation,
inhibitory neural reexes, and neurohormonal
peptides. Logically, the risk of POI is higher with
intraabdominal surgeries and perioperative opioid
use. Common clinical symptoms of POI include
nausea and vomiting, inability to tolerate an oral
diet, absence of atus, abdominal distention, and
radiologic conrmation without an alternative
mechanical cause. Figure 8.2 shows an impres-

8 Medical Management oftheLimb Salvage Inpatient
101
sive abdominal radiograph of a megacolon measuring 16.3cm.
Initiation of treatment for prolonged POI
(greater than 3 postoperative days) is focused on
supportive care. Interventions such as management of pain with avoidance of opioid agents,
bowel rest and decompression if indicated, electrolyte replacement, and nutritional support are
common ways to shorten the course of POI.While
uid replacement is also an important factor of
supportive therapy, it is important to mention that
studies have shown that overly aggressive uid
resuscitation in the perioperative setting could
lead to edema in the gastrointestinal tract and
may actually lead to postoperative ileus [71]. The
use of prokinetic agents remains controversial as
studies have shown limited utility.
Antibiotics Associated Diarrhea
The rst step in evaluating the cause of a patient’s
diarrhea is to look over the patient’s existing
bowel regimen and eliminate any offending
agents as the possible cause of symptoms. Next,
the most concerning diagnosis in a patient with
antibiotics associated diarrhea is C. difcile colitis and must be properly investigated.
Although any recent antibiotic use can predispose patients to C. Diff. infection, the most
common offending agents are uoroquinolones,
clindamycin, cephalosporins, and penicillins [72].
In addition to antibiotic use, suspicion for C. difcile colitis should arise if the patient has any of
the following: advanced age, recent hospitalization, >3 loose stools per day, unexplained leukocytosis, and abdominal pain. Once there is a clinical
suspicion, the patient should be placed on contact
precautions and tested for C.Diff. via a stool test.
If clinical suspicion and testing is positive, initial treatment for uncomplicated C.Diff. without
evidence of toxic megacolon includes oral vancomycin or oral daxomicin. For recurrent episodes, a prolonged course of vancomycin with a
taper is an option. For fulminant episodes that
include toxic megacolon and hemodynamic
instability, IV metronidazole and oral vancomycin are both recommended along with additional
considerations for rectal vancomycin and fecal
microbiota transplant.
If there is a low clinical suspicion for C.Diff.
colitis or other infectious diarrheal sources, most
antibiotic associated diarrhea can be supportively
managed with proper hydration, antidiarrheal
agents, and consideration of the risk vs. benet of
removing the suspected antibiotic.
Summary ofComplications
The internist follows each patient daily during
the hospital stay in order to detect and treat complications that may arise. Early recognition of
kidney injury, delirium, and gastrointestinal
problems will aide in the treatment and recovery
of the limb salvage inpatient.
Conclusion: Medical Management
oftheLimb Salvage Inpatient
Limb salvage inpatients are medically complex
and at substantial risk of complications.
Preparation for surgery involves coordination
between the internal medicine specialist and the
surgical team. Careful review of cardiac status
and risk factors is essential to quantify the perioperative cardiac risk. This evaluation also provides
the opportunity to review a patient’s cardiac medication management and to optimize it prior to surgery. Diabetes is present in the vast majority of
the limb salvage inpatients. The internist reviews
current diabetic medications and control and converts oral medications to insulin. These treatment
decisions must be coordinated daily with the surgical team as the patient will frequently be NPO
for procedures. Anticoagulation management is
critically important in surgical patients due to
competing risks of thrombosis and bleeding. The
internist works with the surgical team to assess
the need for and safety of anticoagulants around
the time of surgery. Lastly, the internist works to
prevent and identify medical complications.
Surgical success is aided by careful control of
medical comorbidities. The importance of close
coordination between the medical and surgical
teams cannot be overemphasized. We have found
the best way to achieve this coordination with

102
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
M. M. Alternburg et al.
daily multidisciplinary rounds in which each
inpatient case is discussed with the surgical and
medical teams.
References
1. Weiser TG, Regenbogen SE, Thompson KD, Haynes
AB, Lipsitz SR, Berry WR, Gawande AA.An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet.
2008;372(9633):139–44.
2. Smilowitz NR, Gupta N, Ramakrishna H, Guo Y,
Berger JS, Bangalore S.Perioperative major adverse
cardiovascular and cerebrovascular events associated with noncardiac surgery. JAMA Cardiol.
2017;2(2):181–7.
3. Gupta PK, Gupta H, Sundaram A, Kaushik M, Fang
X, Miller WJ, Esterbrooks DJ, Hunter CB, Pipinos
II, Johanning JM, Lynch TG, Forse RA, Mohiuddin
SM, Mooss AN. Development and validation of a
risk calculator for prediction of cardiac risk after
surgery. Circulation. 2011;124(4):381–7. https://
doi.org/10.1161/CIRCULATIONAHA.110.015701.
Epub 2011 Jul 5. PMID: 21730309.
4. Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmiecik TE,
Ko CY, Cohen ME. Development and evaluation of
the universal ACS NSQIP surgical risk calculator: a
decision aid and informed consent tool for patients
and surgeons. J Am Coll Surg. 2013;217(5):833–42.
5. Duceppe E, Parlow J, MacDonald P, Lyons K,
McMullen M, Srinathan S, Graham M, Tandon
V, Styles K, Bessissow A, Sessler DI, Bryson G,
Devereaux PJ. Canadian cardiovascular society
guidelines on perioperative cardiac risk assessment
and management for patients who undergo noncardiac
surgery. Can J Cardiol. 2017;33(1):17–32.
6. Reilly DF, McNeely MJ, Doerner D, Greenberg DL,
Staiger TO, Geist MJ, Vedovatti PA, Coffey JE, Mora
MW, Johnson TR, Guray ED, Van Norman GA, Fihn
SD. Self-reported exercise tolerance and the risk of
serious perioperative complications. Arch Intern Med.
1999;159(18):2185–92.
7. Devereaux PJ, Szczeklik W. Myocardial injury after
non-cardiac surgery: diagnosis and management. Eur
Heart J. 2020;41(32):3083–91.
8. Fleisher LA, Fleischmann KE, Auerbach AD,
Barnason SA, Beckman JA, Bozkurt B, DavilaRoman VG, Gerhard-Herman MD, Holly TA, Kane
GC, Marine JE, Nelson MT, Spencer CC, Thompson
A, Ting HH, Uretsky BF, Wijeysundera DN,
American College of Cardiology; American Heart
Association. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of
patients undergoing noncardiac surgery: a report of
the American College of Cardiology/American Heart
Association Task Force on practice guidelines. J Am
Coll Cardiol. 2014;64(22):e77–137.
9. Noordzij PG, Boersma E, Bax JJ, Feringa HH,
Schreiner F, Schouten O, Kertai MD, Klein J, van Urk
H, Elhendy A, Poldermans D. Prognostic value of
routine preoperative electrocardiography in patients
undergoing noncardiac surgery. Am J Cardiol.
2006;97(7):1103–6. https://doi.org/10.1016/j.
amjcard.2005.10.058. Epub 2006 Feb 28. PMID:
16563926.
10. Gold BS, Young ML, Kinman JL, Kitz DS, Berlin J,
Schwartz JS.The utility of preoperative electrocardiograms in the ambulatory surgical patient. Arch Intern
Med. 1992;152(2):301–5. PMID: 1739358.
11. van Klei WA, Bryson GL, Yang H, Kalkman CJ,
Wells GA, Beattie WS.The value of routine preoperative electrocardiography in predicting myocardial infarction after noncardiac surgery. Ann Surg.
2007;246(2):165–70.
12. Rohde LE, Polanczyk CA, Goldman L, Cook EF, Lee
RT, Lee TH. Usefulness of transthoracic echocardiography as a tool for risk stratication of patients
undergoing major noncardiac surgery. Am J Cardiol.
2001;87(5):505–9.
13. Kertai MD, Bountioukos M, Boersma E, Bax
JJ, Thomson IR, Sozzi F, Klein J, Roelandt JR,
Poldermans D. Aortic stenosis: an underestimated risk factor for perioperative complications in
patients undergoing noncardiac surgery. Am J Med.
2004;116(1):8–13.
14. Healy KO, Waksmonski CA, Altman RK, Stetson PD,
Reyentovich A, Maurer MS. Perioperative outcome
and long-term mortality for heart failure patients
undergoing intermediate- and high-risk noncardiac
surgery: impact of left ventricular ejection fraction.
Congest Heart Fail. 2010;16(2):45–9.
15. Wijeysundera DN, Pearse RM, Shulman MA, Abbott
TEF, Torres E, Ambosta A, Croal BL, Granton JT,
Thorpe KE, Grocott MPW, Farrington C, Myles
PS, Cuthbertson BH, METS Study Investigators.
Assessment of functional capacity before major noncardiac surgery: an international, prospective cohort
study. Lancet. 2018;391(10140):2631–40.
16. Das MK, Pellikka PA, Mahoney DW, Roger VL, Oh
JK, McCully RB, Seward JB.Assessment of cardiac
risk before nonvascular surgery: dobutamine stress
echocardiography in 530 patients. J Am Coll Cardiol.
2000;35(6):1647–53.
17. Labib SB, Goldstein M, Kinnunen PM, Schick
EC.Cardiac events in patients with negative maximal
versus negative submaximal dobutamine echocardiograms undergoing noncardiac surgery: importance of
resting wall motion abnormalities. J Am Coll Cardiol.
2004;44(1):82–7.
18. McFalls EO, Ward HB, Moritz TE, Goldman S,
Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp
J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L,
Ellis N, Reda DJ, Henderson WG. Coronary-artery
revascularization before elective major vascular surgery. N Engl J Med. 2004;351(27):2795–804.
19. Smilowitz NR, Berger JS. Perioperative cardiovascular risk assessment and management for non-
Соседние файлы в папке Библиотека им академика М.И. Перельмана
